Vima Therapeutics, a Cambridge, MA-based clinical-stage biotechnology firm, raised $60M in Sequence A funding.
The spherical was led by Atlas Enterprise, with participation from Entry Industries and Canaan.
The corporate intends to make use of the funds to increase operations and its R&D efforts.
Led by CEO and Founder Bernard Ravina, Vima Therapeutics is a clinical-stage biotechnology firm offering remedies of dystonia and associated motion issues by advancing an oral remedy designed to assist sufferers with dystonia enhance management of their motion by concentrating on the basis reason for the illness.
It’s advancing VIM0423 a possible first-in-class oral remedy, in a Part 1 scientific trial, with plans to provoke Part 2 by the fourth quarter of 2025.
Vima’s government officers embody:
- Judith Dunn, PhD, president and head of R&D, has 30+ years of drug growth expertise and has held management roles in biotech and pharma, together with world head of scientific growth at Roche.
- Jessica Charges, chief monetary officer, brings over 20 years of finance and strategic management expertise within the biotech trade. Previous to Vima, she served as chief monetary officer at Floor Oncology.
- Ariel D. Jasie, JD, chief enterprise officer and basic counsel, has over 20 years of trade expertise and has served as chief enterprise officer and basic counsel to a number of non-public biotech firms.
- Tushar Misra, PhD, chief technical officer, has been within the pharmaceutical trade for over 30 years and has labored throughout your complete worth chain from R&D to Commercialization, with management roles at many firms, together with Wyeth, Sepracor, and Takeda.
FinSMEs
30/05/2025
